Asia
Tonghua Dongbao Pharmaceutical, Nanjing King-Friend Secure US Approval for Insulin Aspart Injection; Shares Up 2%
Tonghua Dongbao Pharmaceutical (SHA:600867) said its insulin aspart injection, co-developed with Nanjing King-Friend Pharmaceutical (SHA:603707), received U.S. Food and Drug Administration biologics license application approval, according to a Tuesday filing with the Shanghai Stock Exchange.The injection is indicated to improve blood glucose control through subcutaneous injection, the filing said.Shares of Dongbao rose 2% during afternoon trading on Tuesday.
SHA:600867SHA:603707
